Drug Approval | May 12, 2023
USFDA approves GSK’s respiratory syncytial virus vaccine ‘Arexvy’
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
The companies will leverage their respective proprietary technology platforms
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Subscribe To Our Newsletter & Stay Updated
